Kyverna reports one‑year data from miv‑cel trial showing durable benefits in stiff person syndrome

Kyverna Therapeutics presented one‑year results from its registrational Phase 2 KYSA‑8 trial of the CAR‑T therapy miv‑cel in 26 stiff person syndrome patients. Seventy‑seven percent achieved a clinically meaningful ≥20% improvement in the timed 25‑foot walk and the median walking time was 49% faster than baseline. Most patients remained off chronic immunotherapies and safety was favorable, with no high‑grade CRS or ICANS reported.

The company says the data strengthen its rolling Biologics License Application planned for Q4 2026 and could make miv‑cel the first FDA‑approved treatment for SPS, which may lift the stock and attract investor interest (source).

  • 1The KYSA‑8 trial enrolled 26 adult patients with stiff person syndrome.
  • 2At one year, 77% of patients achieved at least a 20% improvement in the timed 25‑foot walk test.
  • 3Median walking time improved by 49% versus baseline at the one‑year mark.
  • 492% (24 of 26) of patients remained free of chronic immunotherapies for SPS at one year.
  • 5Among the 12 patients who required a walking aid at baseline, 67% (8 of 12) no longer needed assistance after one year.
  • 6No high‑grade cytokine release syndrome or immune effector cell‑associated neurotoxicity syndrome was observed.

Sources